<DOC>
	<DOCNO>NCT01370096</DOCNO>
	<brief_summary>To diagnose pulmonary hypertension , child cardiac catheterization check blood pressure lung . Children pulmonary hypertension high blood pressure lung . The right ventricle heart work pump high pressure . The investigator know best medicine ( ) help child pulmonary hypertension right ventricle fail . The purpose study look effect two different medicine blood pressure lungs child pulmonary hypertension . The investigator hope able choose best medicine child pulmonary hypertension right ventricular failure . The first medicine call vasopressin . It hormone body make . The investigator give intravenous infusion . The investigator think vasopressin work differently different part body . The investigator look see different effect vasopressin lung compare rest body . The second medicine call prostacyclin something body also make . Prostacyclin , give via intravenous infusion , treatment pulmonary hypertension decrease pressure blood vessel . In catheterization laboratory , patient breathe medicine measure specific change blood pressure lung .</brief_summary>
	<brief_title>Vasopressin Inhaled Prostacyclin Pediatric Pulmonary Hypertension</brief_title>
	<detailed_description>Background : Pulmonary hypertension ( PH ) rare , devastate disease affect adult pediatric patient . Mortality high 84 % survival one year 50 % survival five year adult population despite treatment . The cause death typically either right ventricular failure sudden cardiac death , likely secondary pulmonary hypertensive crisis . The resuscitation patient PH cardiac arrest extremely difficult . The use epinephrine , pulmonary vasoconstrictor , resuscitation may impair fill left ventricle . The ideal resuscitation drug ( ) would dilate pulmonary vascular bed help fill leave ventricle constrict systemic vascular bed maintain coronary perfusion . Objectives : The assessment pulmonary vascular reactivity critical clinical management patient pulmonary hypertension ( PH ) . The goal pilot study include determination hemodynamic effect low dose vasopressin infusion effect combination low dose vasopressin infusion inhale prostacyclin population pediatric patient PH . Methods : The investigator propose prospective , pilot study examine acute hemodynamic effect low dose vasopressin infusion combination low dose vasopressin infusion inhale prostacyclin pediatric pulmonary hypertension patient . The investigator anticipate recruit 10 pediatric patient pulmonary hypertension course one year . Study Protocol : The study perform cardiac catheterization laboratory . All subject intubate mechanically ventilate study per laboratory protocol . Sedation anesthesia perform discretion pediatric anesthesiologist provide consistent anesthetic period hemodynamic study . Arterial venous access obtain via femoral approach standard technique . Right leave catheterization perform record hemodynamic measurement baseline pulmonary vasoreactivity test oxygen nitric oxide per usual . Catheterization data collect include right atrial pressure , systolic , diastolic mean pulmonary artery pressure , pulmonary capillary wedge pressure , systemic arterial pressure , cardiac index , pulmonary vascular resistance ( PVR ) index , systemic vascular resistance ( SVR ) index PVR/SVR ratio . After period time allow nitric oxide washout , acute vasoreactivity test assess hemodynamic response low dose vasopressin infusion follow combination low dose vasopressin infusion inhale PGI2 perform .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<criteria>All pediatric patient pulmonary hypertension define mean pulmonary artery pressure ≥ 25mmHg undergoing diagnostic cardiac catheterization clinical purpose potential subject . Subjects must preserve leave ventricular function ( ejection fraction ≥ 40 % ) . Subjects must parental consent enrollment . 1 . Any patient left ventricular dysfunction ( EF &lt; 40 % ) . 2 . Any patient know pulmonary venoocclusive disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>